Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab

被引：6
|
作者：
Vegh, Zsuzsanna [1 ]
Kurti, Zsuzsanna [1 ]
Lakatos, Peter L. [1 ]
机构：
[1] Semmelweis Univ, Dept Med 1, Koranyi S 2A, H-1083 Budapest, Hungary
来源：
DIGESTIVE DISEASES | 2017年 / 35卷 / 1-2期
关键词：
Biosimilar; Inflixinnab; Efficacy; Immunogenicity; Adverse events; INFLAMMATORY-BOWEL-DISEASE; PROSPECTIVE NATIONWIDE COHORT; INNOVATOR INFLIXIMAB; PARALLEL-GROUP; DOUBLE-BLIND; CT-P13; MULTICENTER; ORIGINATOR;
D O I：
10.1159/000449089
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Recently, the use of biosimilar infliximab (IFX) in the treatment of inflammatory bowel diseases has become widespread in some European and non-European countries. Data on the efficacy, safety and immunogenicity from real-life cohorts are accumulating. The first reports showed similar outcomes in the induction and maintenance of remission, mucosal healing, safety and immunogenicity profile to the originator IFX. In the present review, we aimed to summarize the existing knowledge on the efficacy, safety and immunogenicity profile of biosimilar IFX reported from real-life cohorts. (C) 2017 S. Karger AG, Basel
引用
收藏
页码：101 / 106
页数：6
相关论文
共 50 条
  • [1] Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study
    Maurizio Benucci
    Francesca Li Gobbi
    Francesca Bandinelli
    Arianna Damiani
    Maria Infantino
    Valentina Grossi
    Mariangela Manfredi
    Simone Parisi
    Enrico Fusaro
    Alberto Batticciotto
    Piercarlo Sarzi-Puttini
    Fabiola Atzeni
    Francesca Meacci
    [J]. Immunologic Research, 2017, 65 : 419 - 422
  • [2] Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study
    Benucci, Maurizio
    Li Gobbi, Francesca
    Bandinelli, Francesca
    Damiani, Arianna
    Infantino, Maria
    Grossi, Valentina
    Manfredi, Mariangela
    Parisi, Simone
    Fusaro, Enrico
    Batticciotto, Alberto
    Sarzi-Puttini, Piercarlo
    Atzeni, Fabiola
    Meacci, Francesca
    [J]. IMMUNOLOGIC RESEARCH, 2017, 65 (01) : 419 - 422
  • [3] Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety
    Dipasquale, Valeria
    Romano, Claudio
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (06) : 1228 - 1234
  • [4] The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan
    Alawneh, Khaldoon
    Al-Mistarehi, Abdel-Hameed
    Qandeel, Ali
    Jaber, Ruba
    Alomari, Safwan
    Kheirallah, Khalid A.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2022, 2022
  • [5] Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data
    Atzeni, Fabiola
    Gerratana, Elisabetta
    Bongiovanni, Sara
    Talotta, Rossella
    Miceli, Gianfranco
    Salaffi, Fausto
    Sarzi-Puttini, Piercarlo
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (06): : 344 - 349
  • [6] COMPARISON OF IMMUNOGENICITY OF BIOSIMILAR INFLIXIMAB AND ORIGINATOR INFLIXIMAB IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE IN REAL LIFE SETTING
    Wahid, A.
    Muhammed, R.
    [J]. GUT, 2017, 66 : A263 - A263
  • [7] EFFICACY AND SAFETY OF RITUXIMAB ORIGINATOR AND BIOSIMILAR IN PRIMARY SJOGREN'S SYNDROME IN A REAL-LIFE SETTING
    Carubbi, F.
    Alunno, A.
    Cipriani, P.
    Pavlych, V.
    Di Muzio, C.
    Gerli, R.
    Giacomelli, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1481 - 1481
  • [8] Effectiveness and safety of biosimilar infliximab (remsima) in a real-life setting in 84 patients with Crohn's disease and ulcerative colitis
    Gheorghe, C.
    Svoboda, P.
    Dimitriu, A.
    Mateescu, B.
    Kotzev, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S316 - S317
  • [9] GGDM 2016 Current "Real-Life"-Studies on the first Infliximab-Biosimilar (Remsima®) give Treatment Safety for CED
    不详
    [J]. VISCERAL MEDICINE, 2016, 32 (05) : 377 - 377
  • [10] Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab
    Lambert, John
    Wyand, Michael
    Lassen, Cheryl
    Shneyer, Lucy
    Thomson, Elizabeth
    Knight, Alastair
    Willers, Joerg
    Kay, Jonathan
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (04) : 315 - 322
12345